Clinical trials: sponsored by Boehringer Ingelheim
Healthy
This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated
This first-in man trial is designed to investigate the safety and tolerability of BI 894416 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03315936
- Testing
- BI 894416
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Purpura, Thrombocytopenic, Idiopathic
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.
- Trial name
- NCT02009761
- Testing
- BI 655064
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Boehringer Ingelheim
Healthy
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers
The aim of this study is to investigate the safety and tolerability of BI 655130 in healthy male subjects following single rising low, medium and high doses.
- Trial name
- NCT02525679
- Testing
- BI 655130 (spesolimab)
- Where
- Belgium
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection
The main objective of this trial is to compare the pharmacokinetics (PK) of 40 mg BI 695501 100 mg/mL with 40 mg BI 695501 50 mg/mL following single subcutaneous administration.
- Trial name
- NCT05203289
- Testing
- BI 695501 - higher concentration, BI 695501 - lower concentration
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other
The primary objective of this trial is to investigate the effect of multiple doses of ethinylestradiol / levonorgestrel (Microgynon®) on single dose pharmacokinetics of BI 409306 and the effect of single dose of BI 409306 on…
- Trial name
- NCT03193307
- Testing
- Microgynon® 30, BI 409306
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.
- Trial name
- NCT04602221
- Testing
- Lamotrigine, BI 409306, BI 425809
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Safety and Effectiveness of Nintedanib in Korean Patients
The objectives of this study are to monitor the safety and effectiveness of Ofev in Korean patients in a routine clinical practice setting.
- Trial name
- NCT04525547
- Testing
- Nintedanib
- Where
- 22 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Boehringer Ingelheim
Healthy
This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)
The primary objective of this trial is to assess the effect of BI 409306 on the QT/QTc interval in healthy male and female volunteers as measured by the QTcF change from baseline compared with placebo.
- Trial name
- NCT03934203
- Testing
- BI 409306, Moxifloxacin
- Where
- Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of daily use of JARDIANCE® Tablets in Japanese elderly patients with type 2 diabetes mellitus.
- Trial name
- NCT02367131
- Testing
- JARDIANCE®
- Where
- Japan
- Volunteers
- 419 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 474121 in the Blood
The main objective of this trial is to investigate the effect on the exposure of BI 474121 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, T) as compared to when given alone as…
- Trial name
- NCT04716894
- Testing
- BI 474121, Itraconazole
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses
The primary objective of this trial was to investigate safety and tolerability of multiple doses of BI 409306 in healthy young and elderly volunteers.
- Trial name
- NCT01505894
- Testing
- BI 409306
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid
The main objectives of this trial are: To evaluate the effect of BI 474121 on cyclic guanosine monophosphate (cGMP) levels in cerebrospinal fluid (CSF) To assess the exposure of BI 474121 in CSF relative to plasma To determine…
- Trial name
- NCT04672954
- Testing
- 2.5 milligram (mg) BI 474121, 10 milligram (mg) BI 474121, 20 milligram (mg) BI 474121
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in healthy young and elderly male and female volunteers following oral administration of repeated rising doses, given once…
- Trial name
- NCT01611311
- Testing
- BI 409306
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated
The main objectives of this trial are to investigate safety and tolerability of BI 474121 in healthy male and female young and elderly subjects following oral administration of multiple rising doses per day over 14 days.
- Trial name
- NCT04537897
- Testing
- BI 474121, Midazolam
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Atrial Fibrillation
A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin
The study aims to evaluate the safety and effectiveness comparisons between warfarin, dabigatran, and rivaroxaban in routine clinical practice among Japanese non-valvular atrial fibrillation (NVAF) patients with concomitant…
- Trial name
- NCT05051904
- Where
- Germany
- Volunteers
- 39,357 people
- Sponsor
- Boehringer Ingelheim
Healthy
Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers
The aim of this study is to assess the mass balance recovery from excreta of carbon 14 labelled BI409306 ([14C] BI 409306) in healthy, CYP2C19 genotyped subjects and to provide plasma, urine and faecal samples for metabolite…
- Trial name
- NCT02597998
- Testing
- 14C-BI 409306
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How BI 474121 is Tolerated
Safety, tolerability, and pharmacokinetics of BI 474121 will be assessed in healthy Japanese male using single rising oral doses in order to provide the basis for an ongoing clinical development of BI 474121 for the treatment of…
- Trial name
- NCT04964453
- Testing
- BI 474121
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers
The primary objective of this trial is to investigate the relative bioavailability of BI 409306 tablets with prior 7-day intake of rifampicin tablets (Test, T) compared to BI 409306 tablets without prior administration of…
- Trial name
- NCT03151499
- Testing
- BI 409306, Rifampicin
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects
The primary objective of this trial is to investigate the safety and tolerability of spesolimab following administration of single rising intravenous doses and single subcutaneous dose in healthy Japanese male volunteers.
- Trial name
- NCT03123094
- Testing
- Spesolimab
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neoplasms
This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
This study is open to adults with different types of advanced cancer (solid tumours). This study is open to people in whom previous treatments were not successful.
- Trial name
- NCT03604445
- Testing
- BI 905677
- Where
- 5 sites in United States, Japan and 2 more
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.